New Preferred Characteristics for Monoclonal Antibodies in Malaria Prevention
Passive immunization through monoclonal antibodies (mAbs) could potentially provide immediate protection against malaria. To guide the development of urgently needed health products, WHO has published preferred product characteristics (PPCs) for mAbs in malaria prevention. These PPCs aim to reduce morbidity and mortality in infants and children due to Plasmodium falciparum, and highlight the preferred characteristics and clinical development considerations for mAbs in this area. This is an exciting development alongside the development of new malaria vaccines and chemoprevention drugs.
Recent Posts
Enhancing Tuberculosis Outcomes Through Counselling Incentives
Tuberculosis counselling incentives that combine conditional cash transfers with structured pre- and post-test counselling are proving highly effective at overcoming socioeconomic barriers to treatment adherence. This integrated strategy reduces long-term disease transmission while requiring only...
Advancing Biovac Vaccine Manufacturing for Africa’s Health Sovereignty
South Africa is strengthening continental health security through a major expansion of Biovac vaccine manufacturing at its Cape Town facility, scheduled for completion in 2028. The project will deliver 30–40 million annual doses of vaccines against cholera, polio, pneumonia, and meningitis while ...
Alora Medical RespiPEP Award Receives Global Recognition
Alora Medical RespiPEP Award marks a major milestone for the South African firm, which earned the Best Lung Clearing Device Brand 2026 title at the Global Health & Pharma Healthcare & Pharmaceutical Awards for its RespiPEP range. This achievement underscores the company’s role in expandin...